Edgar Petru

Medical University of Graz

Austria

Research Interests

Explore related searches

Professors in Austria

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (10)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Collaborators (4)

Ioana Braicu

Head of clinical and translational research

Charité - Universitätsmedizin Berlin

GERMANY

View details

Christof Vulsteke

University of Antwerp

BELGIUM

View details

Marija Balic

Section chief for Medical Breast Oncology

University of Pittsburgh Medical Center

UNITED STATES

View details

Maria Del Grande

University Hospital Basel

SWITZERLAND

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Edgar Petru

Research Interests

Explore related searches

Contact this professor

Articles (10)

First-Line Lenvatinib Plus Pembrolizumab Versus Chemotherapy for Advanced Endometrial Cancer: A Randomized, Open-Label, Phase III Trial

Neoadjuvant atezolizumab in combination with dual HER2 blockade plus epirubicin in women with early HER2-positive breast cancer: the randomized phase 2 ABCSG-52/ATHENE trial

Endometrial cancer—news from ASCO 2024

HER2 and HER3 expression during neoadjuvant treatment of HER2-negative early breast cancer: potential for biomarker-driven sequencing of T-DXd and HER3-DXd

Patient-reported outcomes from the phase 3, randomized, double-blind, placebo-controlled ENGOT-cx11/GOG-3047/KEYNOTE-A18 study of pembrolizumab plus concurrent chemoradiotherapy in participants with high-risk locally advanced cervical cancer

Robust Assessment of Homologous Recombination Deficiency Genomic Instability by OncoScan Microarrays

Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trial

Olaparib Addition to Maintenance Bevacizumab Therapy in Ovarian Carcinoma With BRCA -Like Genomic Aberrations

Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 trial

Single-agent metronomic versus weekly oral vinorelbine as first-line chemotherapy in patients with HR-positive/HER2-negative advanced breast cancer: The randomized Tempo Breast study

Collaborators (4)

Ioana Braicu

Christof Vulsteke

Marija Balic

Maria Del Grande

Make your next move.